|
|
|
Evidence from in vitro and in vivo studies suggests that ITCs and indoles may prevent or inhibit breast cancer development through the following mechanisms modulating activity of phase I and phase II enzymes 6 8, inhibiting cell proliferation 9 14, regulating the expression of estrogen receptor 15, altering the metabolism of estrogen 16 19, or suppressing cyclooxygenase 2 COX 2 20, 21 stromectol for animals |
|
